Aura BiosciencesAURA
About: Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Employees: 89
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
217% more call options, than puts
Call options by funds: $1.09M | Put options by funds: $343K
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
20% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 25
9% more funds holding
Funds holding: 74 [Q2] → 81 (+7) [Q3]
6% more capital invested
Capital invested by funds: $310M [Q2] → $329M (+$19.4M) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
8.4% less ownership
Funds ownership: 82.71% [Q2] → 74.31% (-8.4%) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Edward White 28% 1-year accuracy 39 / 140 met price target | 162%upside $22 | Buy Reiterated | 14 Nov 2024 |
Scotiabank George Farmer 29% 1-year accuracy 6 / 21 met price target | 173%upside $23 | Sector Outperform Maintained | 18 Oct 2024 |
BTIG Robert Hazlett 0% 1-year accuracy 0 / 3 met price target | 185%upside $24 | Buy Maintained | 18 Oct 2024 |
HC Wainwright & Co. Edward White 28% 1-year accuracy 39 / 140 met price target | 162%upside $22 | Buy Maintained | 18 Oct 2024 |